Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

sbriet in Spain and the Netherlands in the fourth quarter of this year.

First Quarter 2013 Financial Results (Unaudited)
InterMune reported total Esbriet revenue in the first quarter of 2013 of $10.5 million, compared with $4.9 million in the first quarter of 2012, an increase of 114 percent.  Sequentially, Esbriet revenue in the first quarter of 2013 increased 28 percent from $8.2 million in the fourth quarter of 2012. 

Research and development (R&D) expenses in the first quarter of 2013 were $25.9 million compared with $23.2 million in the first quarter of 2012, an increase of 12 percent.  Higher R&D expenses reflect increased expenses primarily due to conduct of the ASCEND trial, which enrollment was completed on January 9, 2013.Selling, general and administrative (SG&A) expenses were $30.0 million in the first quarter of 2013, compared with $26.3 million in the same period a year earlier, an increase of 14 percent.  The increased spending for the three-month period in 2013 compared with the same period in 2012 is attributed to the continued development of InterMune's commercial infrastructure and investments in the pre-launch and launches of Esbriet in Europe and Canada.InterMune reported a net loss for the first quarter of 2013 of $49.9 million, or $0.64 per share, compared with a net loss of $46.6 million, or $0.72 per share, in the first quarter of 2012.  Per share amounts included gains from the role of Actimmune® (interferon gamma-1b) in discontinued operations of $0.01 per share and $0.03 per share in the first quarters of 2013 and 2012, respectively.As a result of the June 19, 2012 divestiture of Actimmune, historical Actimmune revenue, cost of goods sold, operating costs, and tax impact are reported in discontinued operations in this and future financial statements and therefore do not appear in the comparisons above regarding on-going operations.

As of March 31, 2013, Int
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... ... The latest addition to the Mettler-Toledo PCE portfolio is the newly ... pharmaceutical and healthcare industry can use the LSS to print track-and-trace labels for their ... can be fully integrated into the production line and is also available as a ...
(Date:9/3/2015)... 3, 2015  Guardant Health®, the leader in ... the performance and clinical utility of Guardant360® on ... and poster presentations at the International Association for ... on Lung Cancer. These abstracts were submitted by ... Davis; the University of Chicago; Sarah Cannon Research ...
(Date:9/3/2015)... 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., a leader ... study " Sensitivity of a rapid point of care ... its affinity for HIV gp41 IgM antibodies " has ... study highlights INSTI,s ability to detect early HIV infection.  ... the 8 th annual International AIDS Society Conference, ...
(Date:9/3/2015)... 3, 2015 According to a ... (LC (HPLC, UHPLC, Flash), GC, Other Components (Autosamplers, Detectors, ... Vials) - Analysis & Global Forecasts to 2020", published ... reach around 9.223 Billion by 2020 from USD 7.062 ... Browse 141 tables and 36 figures spread through ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4
... ... Akt/mTOR inhibitor -, JAMAICA ... has presented three presentations at the 2008,annual meeting of the ... P529 is a non-steroidal, synthetic, small molecule dual acting,anti-angiogenic ...
... DEERFIELD, Ill., April 15 , What and ... CHICAGO (Carotid,intima-media tHICkness in Atherosclerosis using pioGlitazOne) published,today ... thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was,associated with ... when compared to glimepiride., The increased effect ...
... /PRNewswire/ - The acceptance of Peros, oral,delivery platform ... achievement by Benchmark Biolabs, a full service,biopharmaceutical product ... oversees the operation and,management of the Peros production ... biotechnology campus in Lincoln, NE., By obtaining ...
Cached Biology Technology:Paloma Pharmaceuticals to Present at the American Association for Cancer Research 2Paloma Pharmaceuticals to Present at the American Association for Cancer Research 3Paloma Pharmaceuticals to Present at the American Association for Cancer Research 4New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Another industry first enabled by Benchmark Biolabs - Peros' oral delivery platform and vaccine facility licensed by the USDA 2
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/24/2015)... South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its ... with the "2015 African Biometrics Company of the Year Award". ... Nigeria .   -Cross reference: ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... -- Sequella, Inc., a clinical-stage biopharmaceutical company focused ... potential, announced today that the U.S. Food and ... (EMEA) independently reviewed Sequella lead drug compound, SQ109, ... for the treatment of tuberculosis. SQ109 shows excellent ...
... October 22, 2007 (TORONTO) Height may point to ... released by the Centre for Addiction and Mental Health ... on average than males without a sexual attraction to ... A Journal of Research and Treatment, suggests that pedophiles ...
... collaboration, more than 200 medical and scientific journals ... relationship between poverty and human development. The initiative, ... presentations on seven of the journal articles which ... of Health on Monday, October 22, 2007. ...
Cached Biology News:Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 2Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 3200 journals join in theme issues on poverty and human development 2200 journals join in theme issues on poverty and human development 3200 journals join in theme issues on poverty and human development 4200 journals join in theme issues on poverty and human development 5
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Biology Products: